Abstract
Sinonasal carcinoma with neuroendocrine differentiation (SCND) is a rare group of tumors known for their aggressive behavior and poor response to treatment. The data in the literature are sparse and cover a wide range of therapeutic approaches over a protracted timeline. Therefore, it is important that institutions report on their experience with these rare neoplasms. Clinical data, such as age at diagnosis, gender, tumor subtype and stage, treatment intention and modality, recurrence, salvage treatment, and survival of patients with a SCND, diagnosed at our department between 1980 and 2010, were retrospectively analyzed. Fifteen patients were available for analysis; eight with sinonasal undifferentiated carcinoma (SNUC), five with sinonasal neuroendocrine carcinoma (SNEC), and two with small cell neuroendocrine carcinoma (SmCC). The median age at the time of diagnosis was 68 years (range 28–87). Treatment consisted of surgery (2), radiotherapy (4), a combination of these modalities (6) and palliation (3). The estimated 5-year overall survival was 60 % for SNEC, 44 % for SNUC and 0 % for SmCC. According to our institutional experience an aggressive multi-modality approach incorporating (neoadjuvant) chemoradiotherapy, radical surgery and elective treatment of the neck is the best treatment strategy for SCND. The high propensity for distant metastasis and poor prognosis of SmCC warrants consideration of the impact of treatment on the remaining quality of life in these patients.
References
Rosenthal DI, Barker JL Jr, El-Naggar AK, Glisson BS, Kies MS, Diaz EM Jr, Clayman GL, Demonte F, Selek U, Morrison WH, Ang KK, Chao KS, Garden AS (2004) Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 101:2567–2573
Iezzoni JC, Mills SE (2005) “Undifferentiated” small round cell tumors of the sinonasal tract: differential diagnosis update. Am J Clin Pathol 124(Suppl):S110–S121
Fried D, Zanation AM, Huang B, Hayes N, Morris DE, Rosenman J, Varia M, Funkhouser W, Weissler M, Chera BS (2012) Management of nonesthesioneuroblastoma sinonasal malignancies with neuroendocrine differentiation. Laryngoscope 122:2210–2215
Mitchell EH, Diaz A, Yilmaz T, Roberts D, Levine N, Demonte F, Hanna EY, Kupferman ME (2012) Multimodality treatment for sinonasal neuroendocrine carcinoma. Head Neck 34:1372–1376
Lin EM, Sparano A, Spalding A, Eisbruch A, Worden FP, Heth J, Sullivan SE, Thompson BG, Marentette LJ (2010) Sinonasal undifferentiated carcinoma: a 13-year experience at a single institution. Skull Base 20:61–67
Babin E, Rouleau V, Vedrine PO, Toussaint B, de Raucourt D, Malard O, Cosmidis A, Makaeieff M, Dehesdin D (2006) Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. J Laryngol Otol 120(4):289–297
Kim BS, Vongtama R, Juillard G (2004) Sinonasal undifferentiated carcinoma: case series and literature review. Am J Otolaryngol 25:162–166
Musy PY, Reibel JF, Levine PA (2002) Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope 112:1450–1455
Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J, Rosenthal S, Joseph M, Amrein P (2002) Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 94:2623–2634
Smith SR, Som P, Fahmy A, Lawson W, Sacks S, Brandwein M (2000) A clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma. Laryngoscope 110:1617–1622
Acknowledgments
None.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van der Laan, T.P., Bij, H.P., van Hemel, B.M. et al. The importance of multimodality therapy in the treatment of sinonasal neuroendocrine carcinoma. Eur Arch Otorhinolaryngol 270, 2565–2568 (2013). https://doi.org/10.1007/s00405-013-2554-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-013-2554-5